Stem cell therapy is one way thegovernments preparing for a nationimpacted by nuclear disaster.

Cellerant Therapeutics has received $47.5 million from the government to develop its treatment for radiation poisoning. If approved, the feds could buy the drug for the Strategic National Stockpile, which is a part of Project Bioshield- a portion of the Bush-era War on Terror that medically readies the nation against chemical, biological, radiological or nuclear attacks.

This is part of a $163.8 million commitment from theBiomedical Advanced Research and Development Authority, or BARDA.

The new dollars will go toward San Carlos, California-based Cellerants Phase 2 trial in patients with acute myeloid leukemia, as well as the preclinical trials to treat radiation poisoning, or Acute Radiation Syndrome.

As it relates toradiation poisoning, Cellerant said its drugCLT-008 is meant to provide hematopoietic support after exposure to ionizing radiation such as from a nuclear or radiological weapon, or from a nuclear accident, it said in a statement.

The privately held company also recently wrapped up early-stage clinical studies in patients with acute myeloid leukemia, as well as in patients that are undergoing an umbilical cord blood transplant. Cellerant found CLT-008, was safely tolerated in 75 patients, it said in a statement. Its Phase 2 is testing for a decrease in risk of febrile neutropenia, and infections stemming from chemo.

CLT-008 is essentially a collection of deep-freezed stem cells that can ultimately defrost and mature into working granulocytes, platelets and red blood cells in a person. In nonclinical models, Cellerant has shown that the treatments highly effective in providing protection from lethal radiation, preventing infection, facilitating stem cell engraftment and improving overall survival.

Get our daily newsletter or follow us.

Please enter your email below:

Originally posted here:
Feds give Cellerant $47.5M for stem cell treatment that preps for nuclear disaster